Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | MicrobiomeTrials← Back to trialsNCT05771480
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-08-16Est. Completion: 2025-10-02
Enrollment target: 142 participants Locations- Research Site, Mobile, Alabama, United States
- Research Site, Orange, California, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Portland, Oregon, United States
- Research Site, Clichy, France
- Research Site, Dijon, France
- Research Site, Montpellier, France
- Research Site, Villejuif, France
- Research Site, Chemnitz, Germany
- Research Site, Hanover, Germany
- Research Site, Castelfranco Veneto, Italy
- Research Site, Foggia, Italy
- Research Site, Palermo, Italy
- Research Site, Pisa, Italy
- Research Site, Rozzano, Italy
- Research Site, Chūōku, Japan
- Research Site, Kanazawa, Japan
- Research Site, Kashiwa, Japan
- Research Site, Kyoto, Japan
- Research Site, Osaka, Japan
- Research Site, Sendai, Japan
- Research Site, Ube, Japan
Other microbiome trials you might be interested in
Decompensated Liver CirrhosisPrimary Biliary CholangitisPrimary Sclerosing CholangitisHepato-cellular Carcinoma
Intro:
The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europ…
Vienna, AustriaEst. completion Mar 2028
Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of …
Research Site, Wakayama, JapanResearch Site, Yokohama, JapanResearch Site, Singapore, SingaporeResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Seoul, South KoreaResearch Site, Barcelona, SpainResearch Site, Madrid, SpainResearch Site, Madrid, SpainResearch Site, Madrid, SpainResearch Site, Pamplona, SpainResearch Site, Seville, SpainOrange, United States
Est. completion Nov 17, 2026